Clinical Study On The Treatment Of Advanced NSCLC With Gefitinib-related Rash (heat-toxin-stasis Syndrome) With Modified Wuwei Xiaoduyin

Objective: To observe the curative clinical efficacy and safety of Wuweixiaoduyin Decoction in the treatment of Gefitinib-related rash in advanced non-small cell lung cancer(heat toxicity stasis syndrome),and provide reference for the promotion of this prescription in clinical application.Methods: 60 patients who met the requirements were randomly divided into two a randomized controlled trial.The patients in the treatment group were treated with Wuweixiaoduyin Decoction combined with mupiroxin ointment for external treatment,and the patients in the control group were with mupiroxin ointment for external treatment,Dermatology Life Quality Index(DLQI),rash grading,safety before and after treatment(liver and kidney function,blood routine)were observed in the two groups.Results: The total effective rate of the treatment group was 86.67%,and the total effective rate of the control group was 53.33%.The difference was statistically significant(P<0.05),DLQI score of treatment group was significant lower than control group.The difference was statistically significant(P<0.05).Compared with the control group,the total effective rate of the treatment group was 93.33%,which was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).During the treatment period,there were no adverse conditions such as disease progression withdrawal and liver and kidney insufficiency in the two group.Conclusion: Wuweixiaoduyin can alleviate clinical symptoms and improve patients’ quality of life when treating advanced NSCLC patients with gefitinib-related rash(heat toxicity and stasis syndrome).